US20170299491A1 - Use of tumor dissociation reagent in flow cytometry - Google Patents
Use of tumor dissociation reagent in flow cytometry Download PDFInfo
- Publication number
- US20170299491A1 US20170299491A1 US15/486,562 US201715486562A US2017299491A1 US 20170299491 A1 US20170299491 A1 US 20170299491A1 US 201715486562 A US201715486562 A US 201715486562A US 2017299491 A1 US2017299491 A1 US 2017299491A1
- Authority
- US
- United States
- Prior art keywords
- tumor
- dissociation reagent
- dissociation
- reagent
- tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 101
- 238000010494 dissociation reaction Methods 0.000 title claims abstract description 75
- 230000005593 dissociations Effects 0.000 title claims abstract description 75
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 51
- 238000000684 flow cytometry Methods 0.000 title claims abstract description 19
- 210000004027 cell Anatomy 0.000 claims abstract description 67
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 claims abstract description 27
- 102000007260 Deoxyribonuclease I Human genes 0.000 claims abstract description 26
- 108010008532 Deoxyribonuclease I Proteins 0.000 claims abstract description 26
- 108010003272 Hyaluronate lyase Proteins 0.000 claims abstract description 25
- 102000001974 Hyaluronidases Human genes 0.000 claims abstract description 25
- 229960002773 hyaluronidase Drugs 0.000 claims abstract description 25
- 102000029816 Collagenase Human genes 0.000 claims abstract description 17
- 108060005980 Collagenase Proteins 0.000 claims abstract description 17
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims abstract description 17
- 229960002424 collagenase Drugs 0.000 claims abstract description 16
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims abstract description 15
- 102000004142 Trypsin Human genes 0.000 claims abstract description 12
- 108090000631 Trypsin Proteins 0.000 claims abstract description 12
- 239000012588 trypsin Substances 0.000 claims abstract description 12
- 230000015556 catabolic process Effects 0.000 claims abstract description 3
- 238000006731 degradation reaction Methods 0.000 claims abstract description 3
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims description 26
- 102000004169 proteins and genes Human genes 0.000 claims description 20
- 108090000623 proteins and genes Proteins 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 17
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 14
- 239000012528 membrane Substances 0.000 claims description 14
- 102000005962 receptors Human genes 0.000 claims description 14
- 108020003175 receptors Proteins 0.000 claims description 14
- 230000001900 immune effect Effects 0.000 claims description 8
- 239000003550 marker Substances 0.000 claims description 8
- 101150030213 Lag3 gene Proteins 0.000 claims description 6
- 102000017578 LAG3 Human genes 0.000 claims description 5
- 210000002865 immune cell Anatomy 0.000 claims description 5
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 4
- 102000008096 B7-H1 Antigen Human genes 0.000 claims description 4
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims description 4
- 108091008028 Immune checkpoint receptors Proteins 0.000 claims description 4
- 102000037978 Immune checkpoint receptors Human genes 0.000 claims description 4
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 abstract description 15
- 101100510617 Caenorhabditis elegans sel-8 gene Proteins 0.000 abstract description 12
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 abstract description 12
- 238000003556 assay Methods 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 description 47
- 238000011282 treatment Methods 0.000 description 23
- 229940088598 enzyme Drugs 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- 239000006285 cell suspension Substances 0.000 description 11
- 102000038379 digestive enzymes Human genes 0.000 description 11
- 108091007734 digestive enzymes Proteins 0.000 description 11
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 10
- 238000001514 detection method Methods 0.000 description 9
- 210000004379 membrane Anatomy 0.000 description 9
- 238000010186 staining Methods 0.000 description 7
- 239000000872 buffer Substances 0.000 description 6
- 239000007853 buffer solution Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 101710160107 Outer membrane protein A Proteins 0.000 description 4
- 231100000433 cytotoxic Toxicity 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 208000037534 Progressive hemifacial atrophy Diseases 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000006862 enzymatic digestion Effects 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 238000006911 enzymatic reaction Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 210000002443 helper t lymphocyte Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 229940124568 digestive agent Drugs 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 239000003147 molecular marker Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 241000511343 Chondrostoma nasus Species 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 101150046249 Havcr2 gene Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 102000000591 Tight Junction Proteins Human genes 0.000 description 1
- 108010002321 Tight Junction Proteins Proteins 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229940088623 biologically active substance Drugs 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 210000002242 embryoid body Anatomy 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000003761 preservation solution Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229960001322 trypsin Drugs 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/535—Production of labelled immunochemicals with enzyme label or co-enzymes, co-factors, enzyme inhibitors or enzyme substrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/40—Concentrating samples
- G01N1/4044—Concentrating samples by chemical techniques; Digestion; Chemical decomposition
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N15/1456—Optical investigation techniques, e.g. flow cytometry without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals
- G01N15/1459—Optical investigation techniques, e.g. flow cytometry without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals the analysis being performed on a sample stream
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N2015/1006—Investigating individual particles for cytology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
Definitions
- the present disclosure relates to a tumor dissociation reagent useful in flow cytometry for dispersing a clinical solid tumor tissue into a single cell suspension and for protecting the surface marker from being degraded.
- preparation in tissue blocks of the sample into a single cell suspension is required, so as to obtain high-yield cells, and integrity of cells and epitopes is intact and can be used directly in downstream experiments. Only when various cell components of the sample tissue are in a single cell state, a variety of detection and analysis of cell effects can be effectively carried out, while the quality of cell suspension is closely related to digestive fluid formulations and digestion methods.
- the preparation methods of single cell suspension commonly used are chemical, enzymatic and physical methods.
- the cell-to-cell linkages such as collagenase, elastic fiber, mucopolysaccharide, tight junction proteins and the like are mainly destructed for cell dispersion in enzymatic method. Trypsin, collagenase, hyaluronidase and the like are the commonly used enzymes.
- Trypsin has a strong ability to disperse cells with short action time.
- the use of trypsin in preparation of single cell suspension results in high yield, but the conditions of action required by trypsin are complex.
- Trypsin may damage the cell surface antigen and even cells.
- trypsin-treated mouse thymus cell surface receptors CD4 and CD8 are digested by trypsin digestion (Thomas Barthlott, Rebecca J. Wright and Brigitta Stockinger. J Immunol, 1998. 161:3992-3999). Therefore, trypsin is suitable for detection of intracellular antigens but not for cell surface antigens, especially weakly expressed antigens.
- Immunological checkpoint proteins are key targets in tumor therapy and play a very important role in immunotherapy, thus may be a powerful weapon for conquering cancer. Therefore the accuracy of detection is required for diagnosis and treatment of cancer.
- flow cytometry has an incomparable advantage in determination of subdivision and cell surface markers, because it can simultaneously detect multiple markers on a single cell.
- the tumor tissue needs to be treated with a digestive enzyme into a single cell suspension before it can be used for subsequent flow cytometry.
- the current commercial human tumor digestive agents or digestive agents commonly used such as collagenases all have a significant impact on the expression level of various proteins concerned in the present disclosure (including immunological checkpoint proteins such as Tim-3 and Lag3), which undoubtedly increased the risk of misdiagnosis of the disease and easily lead to wrong treatment. Therefore, the digestive effect of dissociation reagent on tumor tissues and the protective effect thereof on cell surface antigen remain to be improved. It is important to find a digestive enzyme or mixture that is effective in digesting human tumor tissues and does not affect the expression of surface markers.
- the present disclosure relates to a tumor dissociation reagent.
- the tumor dissociation reagent which does not comprise collagenase but comprises hyaluronidase, said tumor dissociation reagent does not degrade or partially degrade membrane surface receptor.
- the present disclosure also relates to a tumor dissociation reagent which further does not comprise trypsin and collagenase and comprises hyaluronidase, wherein the tumor dissociation reagent does not degrade or partially degrade membrane surface receptor.
- the concentration range of the hyaluronidase described in an embodiment of the present disclosure is preferably 1 mg/mL or less, and the concentration of hyaluronidase is more preferably 1 ⁇ g/mL to 1 mg/mL.
- the present disclosure further relates to the preceding tumor dissociation reagent, further comprising DNase I.
- the concentration range of the DNase I described in the present disclosure is preferably 50 ⁇ g/mL or less, and the concentration of DNase I is more preferably 1 ⁇ g/mL to 50 ⁇ g/mL.
- the tumor dissociation reagent does not degrade or partially degrade membrane surface receptor, wherein said membrane surface receptor is at least one checkpoint receptor selected from the group consisting of receptor CD8, PD-1, PD-L1, TIM-3 and LAG-3 protein.
- the proceeding membrane surface receptor is a checkpoint receptor.
- the present disclosure provides use of said tumor dissociation reagent in detecting protein expression level of an immunological checkpoint marker in tumor tissue.
- the preceding tumor dissociation reagent further comprises DNase I.
- the tumor tissue includes tumor infiltrating immune cell.
- the protein expression in tumor tissue is detected by flow cytometry.
- the protein is membrane surface receptor for checkpoint.
- said membrane surface receptor is at least one checkpoint receptor selected from the group consisting of CD8, PD-1, PD-L1, TIM-3 and LAG-3 protein.
- the present disclosure relates a kit for tumor dissociation comprising the tumor dissociation reagent of the present disclosure.
- the preceding tumor dissociation reagent further comprises DNase I.
- the present disclosure also relates to use of the kit in detecting protein expression in tumor tissue by flow cytometry.
- the present disclosure also provides a preparation method, wherein the method may prevent degradation of immunological checkpoint markers in tumor tissue, wherein cells are treated with the tumor dissociation agent disclosed by the present disclosure.
- a method of tumor dissociation for flow cytometry comprises dissolving a tumor tissue with the tumor dissociation reagent of the present disclosure.
- the tumor tissue further includes tumor infiltrating immune cell.
- the benefit of the present disclosure resides in the establishment of a tumor dissociation reagent which does not comprise collagenase or trypsin and does not degrade or partially degrade membrane surface marker in tumor tissue, therefore the tumor dissociation reagent is useful in flow cytometry for detecting the expression level of proteins in tumor tissue.
- FIG. 1 is a flow chart showing the checkpoint proteins PD-1, Tim-3, and Lag-3 in helper T cells (CD4+) treated with different digestive enzymes.
- FIG. 2 is a flow chart showing the checkpoint proteins PD-1, Tim-3, and Lag-3 in cytoxic T cells (CD8+) treated with different digestive enzymes.
- FIG. 3 is a graph showing the percentages of cell surface checkpoint proteins after different digestive enzymes treatment.
- FIG. 4 is a graph showing the percentages of cell surface checkpoint proteins PD-1, Tim-3 and Lag-3 after treatment with two-enzyme mixture.
- FIG. 5 is a flow chart showing the cell surface checkpoint proteins CD4 and CD8 after treatment with different digestive enzymes.
- FIG. 6 is a graph showing the cell yield after digestion with different enzymes.
- dissociation reagent refers to an enzymatic digestion reagent
- a tumor dissociation reagent refers to an enzymatic digestion reagent that digests tumor tissue into a single cell suspension with an enzyme digestion solution.
- membrane surface receptor refers to one molecule or a class of molecules on cell surface that may recognize, bind to a specific biologically active substance (referred to as a ligand), and the resulting complex may activate and initiate a series of physical and chemical changes that lead to the final biological effects of the substance. Changes in the various factors of the cell environment result in corresponding changes of the physiological processes within the cell through the role of the cell membrane receptors.
- Dissociation buffer system of Hyaluronidase 50 ⁇ L of a solution of hyaluronidase with an initial concentration of 10 mg/mL (Hyaluronidase, available from Sigma, Cat. No. H3506) was added to 4.95 mL of DMEM medium (the final concentration of hyaluronidase is 100 ⁇ g/mL) and then formulated into 5 mL of dissociation reagent for tumor tissues.
- Dissociation buffer system of Collagenase D 500 ⁇ L of a solution of collagenase D (Collagenase D, available from Roche Corporation, Cat. No. 11088882001) with an initial concentration of 10 mg/mL was added to 4.5 mL of DMEM medium (the final concentration of collagenase D is 1 mg/mL) and then formulated into 5 mL of dissociation reagent for tumor tissues.
- Dissociation buffer system of DNase I 50 ⁇ L of a solution of DNase I (DNase I, available from Sigma Corporation, Cat. No. DN25-1G) with an initial concentration of 5 mg/mL was added to 4.95 mL of DMEM medium (the final concentration of DNase I is 0.05 mg/mL) and then formulated into 5 mL of dissociation reagent for tumor tissues.
- DNase I DNase I, available from Sigma Corporation, Cat. No. DN25-1G
- DMEM medium the final concentration of DNase I is 0.05 mg/mL
- Dissociation buffer system of three-enzyme mixture 50 ⁇ L of a solution of hyaluronidase at the initial concentration of 10 mg/mL, 500 ⁇ L of a solution of collagenase D with an initial concentration of 10 mg/mL and 50 ⁇ L of a solution of DNase I with an initial concentration of 5 mg/mL were added to 4.4 mL of DMEM medium and then formulated into 5 mL of dissociation reagent for tumor tissues.
- Dissociation buffer system of two-enzyme mixture 50 ⁇ L of a solution of hyaluronidase with an initial concentration of 10 mg/mL and 50 ⁇ L of a solution of DNase I with an initial concentration of 5 mg/mL were added to 4.9 mL of DMEM medium and then formulated into 5 mL of dissociation reagent for tumor tissues.
- Dissociation buffer system of Miltenyi Human Tumor Dissociation Kit (Human tumor dissociation kit, Cat. No. 130-095-929): according to the instructions, the storage solution of digestive enzymes A, H, and R with appropriate concentrations are formulated, and then stored at ⁇ 20° C.
- 200 ⁇ L of storage solution of enzyme H, 100 ⁇ L of storage solution of enzyme R and 25 ⁇ L of storage solution of enzyme A were added to 4.7 mL of DMEM medium and then formulated into 5 mL of dissociation solution for tumor tissues.
- the tumor is not a single cell suspension, thus it cannot be used in flow cytometry directly. If mechanical dissociation is used rather than enzymatic dissociation, single-cell yield is relatively low, therefore positive rate of single cell molecular marker proteins obtained by mechanical dissociation may not be able to represent the real value of the whole tissue.
- peripheral blood mononuclear cells were used in the detection of molecular marker proteins of cells. It is confirmed that some dissociation reagent has an effect on the expression level of marker proteins on cell surface.
- PBMC peripheral blood mononuclear cells
- Dissociation Reagent Condition PBMC Negative control 37° C., 15 minutes Miltenyi Human Tumor Dissociation Kit 37° C., 15 minutes (Kit) Three-enzyme mixture 37° C., 15 minutes 1 mg/mL Collagenase D 37° C., 15 minutes 100 ⁇ g/mL Hyaluronidase 37° C., 15 minutes 0.05 mg/mL DNase I 37° C., 15 minutes Two-enzyme mixture 37° C., 15 minutes
- the dissociated cells were centrifuged with a centrifuge (available from Eppendorf, model 5810R) and the supernatant was removed.
- the pellets were washed twice with a phosphate buffer PBS (available from Hyclone Corporation, Cat. No. SH3002802B) and centrifuged to remove the supernatant, and then incubated with formulated antibody mixture at 4° C. for 30 minutes in dark.
- the cells were centrifuged at 4° C., 300 ⁇ g to remove the supernatant.
- the cells were resuspended in 200 ⁇ L of staining buffer for flow cytometry (available from BD Co., Cat. No. Pharmingen-554657) and centrifuged at 4° C., 300 ⁇ g for 5 minutes, and repeated once.
- the cells were re-suspended in 100 ⁇ L of cell fixation buffer (available from BD, Cat. No. BD-554655) and incubated at 4° C. for 20-30 minutes in dark.
- cell fixation buffer available from BD, Cat. No. BD-554655
- the cells were re-suspended in 200 ⁇ L of staining solution (available from BD Co., Cat. No. Pharmingen-554657), centrifuged at 4° C., 300 ⁇ g for 5 minutes and repeated once, and finally re-suspended in staining buffer for flow cytometry (available from BD Company, Cat. No. Pharmingen-554657), and the suspension was transferred to a flow tube with a final volume of 500 ⁇ L and detected with a cytometer (BD FACS Canto II).
- staining solution available from BD Co., Cat. No. Pharmingen-554657
- staining buffer for flow cytometry available from BD Company, Cat. No. Pharmingen-554657
- Tim-3 and Lag-3 proteins in T cells (CD4+) and cytoxic T cells (CD8+) were significantly decreased after treatment with Miltenyi Human Tumor Dissociation Kit for 15 minutes as compared with the negative control.
- the expression levels of Lag-3 protein in helper T cells (CD4+) and cytoxic T cells (CD8+) were significantly decreased after treatment with three-enzyme mixtures or collagenase (as shown in FIG. 1 , FIG. 2 , FIG. 3 and TABLE 3).
- PBMC peripheral blood mononuclear cells
- PBMC Peripheral Blood Mononuclear Cells
- PBMC peripheral blood mononuclear cells
- the obvious adipose tissue, fibrous tissue and necrotic part were removed, and then the resulting clinical tumor samples were washed three times in pre-cooled DMEM medium, finally the tumor tissue were cut into 10 mm 3 small pieces with ophthalmic scissors and tweezers.
- a solution of hyaluronidase with an initial concentration of 10 mg/mL was added to 4.95 mL of DMEM medium (the final concentration is 100 ⁇ s/mL) to prepare the dissociation reagent for tumor tissue, and then 5 mL of prepared dissociation reagent for tumor tissue was put into a C tube dedicated for gentleMACS Dissociator (available from Miltenyi Company, Cat. No. 130-093-237), and the cut tumor tissues were also transferred to the C tube dedicated for Miltenyi tissue treatment with tweezers. After tightening of the lid, the tissue fragments in the dissociation reagent were gently shaken. Tumor tissues within the range of 10 mg to 1000 mg can be treated with this dissociation system.
- the C tube was gently inserted into the C-tube slot of the gentleMACS Dissociator (available from Miltenyi Company, Cat. No. 130-093-235). And it should be noted that the tumor tissue fragments should be concentrated at the blade area within the C tube.
- the program was set to the h_tumor_01, and then run once.
- the C tube was removed after the end of the program h_tumor_01 and placed upward for a while so as to place all tumor fragments in the dissociation solution at the bottom of the tube. If necessary, the lid can be removed and the tissue adhered on the lid can be transferred with tweezers to the bottom dissociation reagent.
- the removed C tube was put into a 37° C. constant temperature water bath for 7 minutes, which can be shook appropriately for several times during the period. Repeat the above steps once.
- the above C tube was gently inserted into the C-tube slot of the Miltenyi Tissue processor.
- the program was set to h_tumor_02, and then run twice.
- the C tube was removed and the tissue dissociation was re-suspended in 20 mL of phosphate buffer.
- a 70 ⁇ m cell strainer (available from falcon, Cat. No. 352350) was placed on a 50 mL centrifuge tube and the dissociated tissue was re-suspended and slowly passed through the 70 ⁇ m cell strainer and, if necessary, the minced fine tissue pieces can be grounded on the strainer to obtain more single-cell suspensions.
- the cell strainer was washed with 20 mL to 30 mL of phosphate buffer so that the final volume of the single-cell suspension obtained through the strainers was 50 mL.
- the cells were centrifuged at 300 ⁇ g for 10 minutes, and the supernatant was removed with a pipette.
- the single cells obtained in the previous step were re-suspended in 40 mL of phosphate buffer and were centrifuged at 300 ⁇ g for 7 min.
- the cells were re-suspended into a single-cell suspension with 0.5 to 5 mL of flow cytometry staining buffer, and counted by staining of trypan blue.
- the clinically obtained patient tumor samples were dissociated with different digestive enzymes under the same temperature and time conditions according to the method of Example 5, and the single-cell yield was counted with trypan blue staining. Each sample was counted three times, and the average number+SEM of single cells per gram of tumor was shown in the figure.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Dispersion Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The present disclosure relates to a dissociation reagent for tumor tissues. The dissociation reagent does not contain collagenase or trypsin but further contains hyaluronidase or a mixture of hyaluronidase and DNase I. The present disclosure also relates to use of the dissociation reagent in dispersing tumor tissues and detecting expression level of molecular markers on cell surface by flow cytometry. The dissociation reagent of the present disclosure does not cause degradation of molecular markers on cell surface such as CD8, PD-1, Tim-3, Lag-3 and the like, thus does not affect downstream assays.
Description
- This application claims priority to Chinese Application No. 201610235031.4 filed on Apr. 15, 2016, which is incorporated herein by reference in its entirety.
- The present disclosure relates to a tumor dissociation reagent useful in flow cytometry for dispersing a clinical solid tumor tissue into a single cell suspension and for protecting the surface marker from being degraded.
- In the analysis of the cell biological characteristics of tumor tissue (such as the detection of cell epitope, etc.), preparation in tissue blocks of the sample into a single cell suspension is required, so as to obtain high-yield cells, and integrity of cells and epitopes is intact and can be used directly in downstream experiments. Only when various cell components of the sample tissue are in a single cell state, a variety of detection and analysis of cell effects can be effectively carried out, while the quality of cell suspension is closely related to digestive fluid formulations and digestion methods. The preparation methods of single cell suspension commonly used are chemical, enzymatic and physical methods.
- The cell-to-cell linkages such as collagenase, elastic fiber, mucopolysaccharide, tight junction proteins and the like are mainly destructed for cell dispersion in enzymatic method. Trypsin, collagenase, hyaluronidase and the like are the commonly used enzymes. In prior art, it is stated that a variety of tissues including tumor tissue, skeletal muscle, spleen, lung, nerve tissue, epidermis, lamina propria, mouse heart, neonatal neurons, embryoid bodies and the like may be treated with commercial dissociation kits such as the Miltenyi Tissue Dissociation Kit; and according to the difference in the sensitivity of the cell surface antigen to enzymatic digestion, different enzyme reaction systems are designed for preventing the cell surface antigen destruction, so as not to affect downstream experiments. In fact, there are some molecular markers on cell surface that are degraded or partially degraded in practices, making it impossible to detect accurately.
- In fact, some commonly used components of the enzymatic reagent will affect the detection of cell surface molecular markers. For example, Trypsin has a strong ability to disperse cells with short action time. The use of trypsin in preparation of single cell suspension results in high yield, but the conditions of action required by trypsin are complex. In addition, Trypsin may damage the cell surface antigen and even cells. For example, trypsin-treated mouse thymus cell surface receptors CD4 and CD8 are digested by trypsin digestion (Thomas Barthlott, Rebecca J. Wright and Brigitta Stockinger. J Immunol, 1998. 161:3992-3999). Therefore, trypsin is suitable for detection of intracellular antigens but not for cell surface antigens, especially weakly expressed antigens.
- Immunological checkpoint proteins are key targets in tumor therapy and play a very important role in immunotherapy, thus may be a powerful weapon for conquering cancer. Therefore the accuracy of detection is required for diagnosis and treatment of cancer.
- In the process of diagnosis and determination of the following treatment regimen (especially targeted therapy) for clinical cancer patients, flow cytometry has an incomparable advantage in determination of subdivision and cell surface markers, because it can simultaneously detect multiple markers on a single cell. However, the tumor tissue needs to be treated with a digestive enzyme into a single cell suspension before it can be used for subsequent flow cytometry. In the present disclosure, we have found that the current commercial human tumor digestive agents or digestive agents commonly used such as collagenases all have a significant impact on the expression level of various proteins concerned in the present disclosure (including immunological checkpoint proteins such as Tim-3 and Lag3), which undoubtedly increased the risk of misdiagnosis of the disease and easily lead to wrong treatment. Therefore, the digestive effect of dissociation reagent on tumor tissues and the protective effect thereof on cell surface antigen remain to be improved. It is important to find a digestive enzyme or mixture that is effective in digesting human tumor tissues and does not affect the expression of surface markers.
- In one aspect, the present disclosure relates to a tumor dissociation reagent.
- Wherein, the tumor dissociation reagent which does not comprise collagenase but comprises hyaluronidase, said tumor dissociation reagent does not degrade or partially degrade membrane surface receptor.
- The present disclosure also relates to a tumor dissociation reagent which further does not comprise trypsin and collagenase and comprises hyaluronidase, wherein the tumor dissociation reagent does not degrade or partially degrade membrane surface receptor.
- Wherein, the concentration range of the hyaluronidase described in an embodiment of the present disclosure is preferably 1 mg/mL or less, and the concentration of hyaluronidase is more preferably 1 μg/mL to 1 mg/mL.
- The present disclosure further relates to the preceding tumor dissociation reagent, further comprising DNase I.
- Wherein, the concentration range of the DNase I described in the present disclosure is preferably 50 μg/mL or less, and the concentration of DNase I is more preferably 1 μg/mL to 50 μg/mL.
- In one embodiment, the tumor dissociation reagent does not degrade or partially degrade membrane surface receptor, wherein said membrane surface receptor is at least one checkpoint receptor selected from the group consisting of receptor CD8, PD-1, PD-L1, TIM-3 and LAG-3 protein.
- In one embodiment, the proceeding membrane surface receptor is a checkpoint receptor.
- In a further aspect, the present disclosure provides use of said tumor dissociation reagent in detecting protein expression level of an immunological checkpoint marker in tumor tissue.
- In one embodiment of the present disclosure, the preceding tumor dissociation reagent further comprises DNase I.
- In one embodiment of the present disclosure, the tumor tissue includes tumor infiltrating immune cell.
- In an embodiment of the present disclosure, the protein expression in tumor tissue is detected by flow cytometry.
- In an embodiment of the present disclosure, the protein is membrane surface receptor for checkpoint.
- In an embodiment of the present disclosure, in flow cytometry of tumor tissue, said membrane surface receptor is at least one checkpoint receptor selected from the group consisting of CD8, PD-1, PD-L1, TIM-3 and LAG-3 protein.
- In a further aspect, the present disclosure relates a kit for tumor dissociation comprising the tumor dissociation reagent of the present disclosure.
- In an embodiment of the present disclosure, the preceding tumor dissociation reagent further comprises DNase I.
- The present disclosure also relates to use of the kit in detecting protein expression in tumor tissue by flow cytometry.
- In a further aspect, the present disclosure also provides a preparation method, wherein the method may prevent degradation of immunological checkpoint markers in tumor tissue, wherein cells are treated with the tumor dissociation agent disclosed by the present disclosure.
- In one embodiment of the present disclosure, a method of tumor dissociation for flow cytometry comprises dissolving a tumor tissue with the tumor dissociation reagent of the present disclosure.
- In one embodiment of the present disclosure, the tumor tissue further includes tumor infiltrating immune cell.
- The benefit of the present disclosure resides in the establishment of a tumor dissociation reagent which does not comprise collagenase or trypsin and does not degrade or partially degrade membrane surface marker in tumor tissue, therefore the tumor dissociation reagent is useful in flow cytometry for detecting the expression level of proteins in tumor tissue.
-
FIG. 1 is a flow chart showing the checkpoint proteins PD-1, Tim-3, and Lag-3 in helper T cells (CD4+) treated with different digestive enzymes. -
FIG. 2 is a flow chart showing the checkpoint proteins PD-1, Tim-3, and Lag-3 in cytoxic T cells (CD8+) treated with different digestive enzymes. -
FIG. 3 is a graph showing the percentages of cell surface checkpoint proteins after different digestive enzymes treatment. -
FIG. 4 is a graph showing the percentages of cell surface checkpoint proteins PD-1, Tim-3 and Lag-3 after treatment with two-enzyme mixture. -
FIG. 5 is a flow chart showing the cell surface checkpoint proteins CD4 and CD8 after treatment with different digestive enzymes. -
FIG. 6 is a graph showing the cell yield after digestion with different enzymes. - The present disclosure is further described by the specific embodiments and experimental results. Although specific terms are used hereinafter for the purpose of clarity, these terms are not to be limiting the scope of the present disclosure.
- As used herein, the term “dissociation reagent” refers to an enzymatic digestion reagent, and in the present disclosure, a tumor dissociation reagent refers to an enzymatic digestion reagent that digests tumor tissue into a single cell suspension with an enzyme digestion solution.
- As used herein, the term “membrane surface receptor” refers to one molecule or a class of molecules on cell surface that may recognize, bind to a specific biologically active substance (referred to as a ligand), and the resulting complex may activate and initiate a series of physical and chemical changes that lead to the final biological effects of the substance. Changes in the various factors of the cell environment result in corresponding changes of the physiological processes within the cell through the role of the cell membrane receptors.
- The experimental methods in the following examples, unless otherwise specified, are conventional methods.
- Dissociation buffer system of Hyaluronidase: 50 μL of a solution of hyaluronidase with an initial concentration of 10 mg/mL (Hyaluronidase, available from Sigma, Cat. No. H3506) was added to 4.95 mL of DMEM medium (the final concentration of hyaluronidase is 100 μg/mL) and then formulated into 5 mL of dissociation reagent for tumor tissues.
- Dissociation buffer system of Collagenase D: 500 μL of a solution of collagenase D (Collagenase D, available from Roche Corporation, Cat. No. 11088882001) with an initial concentration of 10 mg/mL was added to 4.5 mL of DMEM medium (the final concentration of collagenase D is 1 mg/mL) and then formulated into 5 mL of dissociation reagent for tumor tissues.
- Dissociation buffer system of DNase I: 50 μL of a solution of DNase I (DNase I, available from Sigma Corporation, Cat. No. DN25-1G) with an initial concentration of 5 mg/mL was added to 4.95 mL of DMEM medium (the final concentration of DNase I is 0.05 mg/mL) and then formulated into 5 mL of dissociation reagent for tumor tissues.
- Dissociation buffer system of three-enzyme mixture: 50 μL of a solution of hyaluronidase at the initial concentration of 10 mg/mL, 500 μL of a solution of collagenase D with an initial concentration of 10 mg/mL and 50 μL of a solution of DNase I with an initial concentration of 5 mg/mL were added to 4.4 mL of DMEM medium and then formulated into 5 mL of dissociation reagent for tumor tissues.
- Dissociation buffer system of two-enzyme mixture: 50 μL of a solution of hyaluronidase with an initial concentration of 10 mg/mL and 50 μL of a solution of DNase I with an initial concentration of 5 mg/mL were added to 4.9 mL of DMEM medium and then formulated into 5 mL of dissociation reagent for tumor tissues.
- Dissociation buffer system of Miltenyi Human Tumor Dissociation Kit (Human tumor dissociation kit, Cat. No. 130-095-929): according to the instructions, the storage solution of digestive enzymes A, H, and R with appropriate concentrations are formulated, and then stored at −20° C. In the experiment, 200 μL of storage solution of enzyme H, 100 μL of storage solution of enzyme R and 25 μL of storage solution of enzyme A were added to 4.7 mL of DMEM medium and then formulated into 5 mL of dissociation solution for tumor tissues.
- Specific designs of different staining channels on cell surface are shown in Table 1.
-
TABLE 1 Channels used for cell surface molecular markers Channel Blank Isotype 2 Panel 2 FITC — Isotype Tim3 PE — Isotype PD-1 PerCP — CD4 CD4 PE-Cy7 — Isotype Lag-3 APC — CD3 CD3 APC-Cy7 — CD8 CD8 BV421 Live/Dead Live/Dead Live/Dead BV510 — CD45 CD45 - The expression of PD-1, Tim-3 and Lag-3 in cytoxic T cells (CD8+T) and helper T cells (CD4+T) was induced by PHA treatment. Whether or not different digestive enzymes will affect expression levels of the three proteins was analyzed in these two groups of cells.
- The tumor is not a single cell suspension, thus it cannot be used in flow cytometry directly. If mechanical dissociation is used rather than enzymatic dissociation, single-cell yield is relatively low, therefore positive rate of single cell molecular marker proteins obtained by mechanical dissociation may not be able to represent the real value of the whole tissue. Thus, in the present disclosure, peripheral blood mononuclear cells were used in the detection of molecular marker proteins of cells. It is confirmed that some dissociation reagent has an effect on the expression level of marker proteins on cell surface.
- First, cryopreserved human peripheral blood mononuclear cells (PBMC) were revived and then treated with 10 μg/mL of PHA for 48 hours to allow the cells to be activated, followed by counting. The cells were aliquoted into 21 tubes; the number of cells is 3×105 cells per tube. 5 mL of dissociation buffer was added into each tube, while 5 mL of DMEM medium (available from Gibco, Cat. No. 11960-051) was added into negative control tube. The tubes were put into a 37° C. water bath (available from Shanghai Yiyou Company, model THZ-82), and the cells were digested for 15 minutes. The specific information of different treatment groups are as followed:
-
TABLE 2 Dissociation conditions in different treatment groups Name Dissociation Reagent Condition PBMC Negative control 37° C., 15 minutes Miltenyi Human Tumor Dissociation Kit 37° C., 15 minutes (Kit) Three-enzyme mixture 37° C., 15 minutes 1 mg/mL Collagenase D 37° C., 15 minutes 100 μg/mL Hyaluronidase 37° C., 15 minutes 0.05 mg/mL DNase I 37° C., 15 minutes Two-enzyme mixture 37° C., 15 minutes - The dissociated cells were centrifuged with a centrifuge (available from Eppendorf, model 5810R) and the supernatant was removed. The pellets were washed twice with a phosphate buffer PBS (available from Hyclone Corporation, Cat. No. SH3002802B) and centrifuged to remove the supernatant, and then incubated with formulated antibody mixture at 4° C. for 30 minutes in dark.
- The cells were centrifuged at 4° C., 300×g to remove the supernatant. The cells were resuspended in 200 μL of staining buffer for flow cytometry (available from BD Co., Cat. No. Pharmingen-554657) and centrifuged at 4° C., 300×g for 5 minutes, and repeated once.
- The cells were re-suspended in 100 μL of cell fixation buffer (available from BD, Cat. No. BD-554655) and incubated at 4° C. for 20-30 minutes in dark.
- The cells were re-suspended in 200 μL of staining solution (available from BD Co., Cat. No. Pharmingen-554657), centrifuged at 4° C., 300×g for 5 minutes and repeated once, and finally re-suspended in staining buffer for flow cytometry (available from BD Company, Cat. No. Pharmingen-554657), and the suspension was transferred to a flow tube with a final volume of 500 μL and detected with a cytometer (BD FACS Canto II).
- The expression levels of Tim-3 and Lag-3 proteins in T cells (CD4+) and cytoxic T cells (CD8+) were significantly decreased after treatment with Miltenyi Human Tumor Dissociation Kit for 15 minutes as compared with the negative control. Similarly, the expression levels of Lag-3 protein in helper T cells (CD4+) and cytoxic T cells (CD8+) were significantly decreased after treatment with three-enzyme mixtures or collagenase (as shown in
FIG. 1 ,FIG. 2 ,FIG. 3 and TABLE 3). - In contrast, the expression of different cell surface molecular markers such as PD-1, Tim-3, and Lag-3 in the hyaluronidase or DNase I treatment group was unchanged or not significantly decreased as compared with the negative control group (as shown in
FIG. 1 ,FIG. 2 ,FIG. 3 and TABLE 3). This suggests that the treatment of collagenase or Miltenyi Human Tumor Dissociation Kit will affect the expression levels of one or more molecular markers on cell surface such as Tim-3 and Lag-3, which is disadvantageous for further detection in flow cytometry. But the reagents not containing collagenase, such as hyaluronidase or DNase I alone did not affect the expression of these immune cell surface molecular markers under given conditions. This experiment demonstrated that neither DNase I at given dose nor hyaluronidase affected the expression level of the checkpoint proteins. Furthermore, we found that the results of 1 mg/mL hyaluronidase or 1 μg/mL hyaluronidase treatment were consistent with that of 100 μg/mL hyaluronidase treatment that neither one affected the level of cell surface molecular markers such as CD8, PD-1, Tim-3 and Lag-3. Similarly, the expression of PD-1, Tim-3 and Lag-3 were not reduced after treatment with up to 50 μg/mL of DNase I. Although the fluorescence signal of CD8 was significantly reduced and PD-1 positive rate was slightly increased, the fluorescence signal intensities of other immunological checkpoints were not decreased. And treatment with less than 50 μg/mL of DNase I did not affect the detection of molecular markers. - To further verify the protective effect of the hyaluronidase group or DNase I on the cell surface molecular markers, a mixture of DNase I and hyaluronidase was used to treat human peripheral blood mononuclear cells (PBMC) according to above experimental method. The experimental results indicated that the mixture of DNase I and hyaluronidase did not affect the expression level of the checkpoint proteins (as shown in
FIG. 4 and Table 4). This data was also advantageous in the increased selectivity for enzyme species. It is anticipated that in certain tumor samples, the cell yield can be increased while the protein expression level is altered. -
TABLE 3 Positive expression rates (%) of different cell surface molecular markers PD- PD- Tim- Tim- Lag- Lag- Group CD4+ CD8+ 1+/ CD4+ 1+/ CD8+ 3+/ CD4+ 3+/ CD8+ 3+/ CD4+ 3+/CD8+ Negative 55.80 22.80 53.30 58.40 30.80 38.20 29.90 65.00 control Kit 49.10 27.10 59.90 62.60 7.99 11.70 2.74 13.50 Three- 53.70 25.80 58.30 60.50 31.40 35.40 6.05 22.10 enzyme mixture Collage- 53.50 25.20 59.30 60.60 29.70 31.40 5.98 19.80 nase D Hyaluron- 56.10 23.60 45.70 51.80 30.20 37.80 28.70 55.90 idase DNase I 54.10 25.90 48.90 53.10 31.00 34.80 27.40 57.10 -
TABLE 4 Positive expression rate (%) of different cell surface molecular markers after treatment with the two-enzyme mixture PD- PD- Tim- Tim- Lag- Lag- Group CD4+ CD8+ 1+/ CD4+ 1+/ CD8+ 3+/ CD4+ 3+/ CD8+ 3+/ CD4+ 3+/CD8+ Negative 33.7 25.9 59 49.4 40.6 55.2 53.2 79.9 control Two- 42.2 24 68.7 52.2 39.9 64.5 46.1 76.5 enzyme mixture - Cryopreserved human peripheral blood mononuclear cells (PBMC) were revived and then treated with 10 μg/mL of PHA for 48 hours to allow the cells to be activated, followed by counting. The cells were aliquoted, the number of cells is 3×105 cells per tube. 5 mL of dissociation buffer was added into each tube, while 5 mL of DMEM medium (available from Gibco, Cat. No. 11960-051) was added into negative control tube. The tubes were put into a 37° C. water bath (available from Shanghai Yiyou Company, model THZ-82), and the cells were digested for 60 minutes.
- The other steps were the same as that in Example 3, and it was found that the fluorescence intensity of CD8 was decreased after the treatment with the commercial human tumor kit (Accumax Cell Dissociation Solution) for 60 minutes, indicating that the kit treatment reduced the expression level of CD8 (as shown in
FIG. 5 and Table 5). -
TABLE 5 Positive expression rates (%) of cell surface molecular markers CD4 and CD8 after treatment with Kit Group CD4+ CD8+ Negative control 55.80 22.80 Kit; 60 minutes 53.70 13.90 - Clinical samples obtained by operation were placed in prepared MACS tissue preservation solution and transported to WuXi AppTec Co. Ltd. (Shanghai). at 4° C. These tumor samples were treated within 48 hours after surgery. Before treatment of clinical tumor tissues, numbering of the corresponding sample was carried out, and the medical history of the patient, texture and color of the tumor tissues, and clinical information were recorded. Tumor tissues were weighed.
- First, the obvious adipose tissue, fibrous tissue and necrotic part were removed, and then the resulting clinical tumor samples were washed three times in pre-cooled DMEM medium, finally the tumor tissue were cut into 10 mm3 small pieces with ophthalmic scissors and tweezers.
- 50 μL of a solution of hyaluronidase with an initial concentration of 10 mg/mL was added to 4.95 mL of DMEM medium (the final concentration is 100 μs/mL) to prepare the dissociation reagent for tumor tissue, and then 5 mL of prepared dissociation reagent for tumor tissue was put into a C tube dedicated for gentleMACS Dissociator (available from Miltenyi Company, Cat. No. 130-093-237), and the cut tumor tissues were also transferred to the C tube dedicated for Miltenyi tissue treatment with tweezers. After tightening of the lid, the tissue fragments in the dissociation reagent were gently shaken. Tumor tissues within the range of 10 mg to 1000 mg can be treated with this dissociation system.
- The C tube was gently inserted into the C-tube slot of the gentleMACS Dissociator (available from Miltenyi Company, Cat. No. 130-093-235). And it should be noted that the tumor tissue fragments should be concentrated at the blade area within the C tube.
- The program was set to the h_tumor_01, and then run once. The C tube was removed after the end of the program h_tumor_01 and placed upward for a while so as to place all tumor fragments in the dissociation solution at the bottom of the tube. If necessary, the lid can be removed and the tissue adhered on the lid can be transferred with tweezers to the bottom dissociation reagent. The removed C tube was put into a 37° C. constant temperature water bath for 7 minutes, which can be shook appropriately for several times during the period. Repeat the above steps once.
- The above C tube was gently inserted into the C-tube slot of the Miltenyi Tissue processor. The program was set to h_tumor_02, and then run twice. The C tube was removed and the tissue dissociation was re-suspended in 20 mL of phosphate buffer. A 70 μm cell strainer (available from falcon, Cat. No. 352350) was placed on a 50 mL centrifuge tube and the dissociated tissue was re-suspended and slowly passed through the 70 μm cell strainer and, if necessary, the minced fine tissue pieces can be grounded on the strainer to obtain more single-cell suspensions. The cell strainer was washed with 20 mL to 30 mL of phosphate buffer so that the final volume of the single-cell suspension obtained through the strainers was 50 mL.
- The cells were centrifuged at 300×g for 10 minutes, and the supernatant was removed with a pipette.
- The single cells obtained in the previous step were re-suspended in 40 mL of phosphate buffer and were centrifuged at 300×g for 7 min.
- The cells were re-suspended into a single-cell suspension with 0.5 to 5 mL of flow cytometry staining buffer, and counted by staining of trypan blue.
- The clinically obtained patient tumor samples were dissociated with different digestive enzymes under the same temperature and time conditions according to the method of Example 5, and the single-cell yield was counted with trypan blue staining. Each sample was counted three times, and the average number+SEM of single cells per gram of tumor was shown in the figure.
- In
FIG. 6 , although the cell yield varies depending on the tumor species or states between different samples, it is comparable between the combination of the three enzymes involved in the present disclosure and the conventional enzyme combination methods reported in the literature, and the differences of cell yield were not large, thus the resulting cells were sufficient for further flow cytometry analysis. - Although the present disclosure is not limited thereto, it will be understood by those skilled in the art that various modifications and variations can be made within the scope of the present disclosure, the manner of changes are also within the scope of the present disclosure.
Claims (18)
1. A tumor dissociation reagent which does not comprise collagenase but comprises hyaluronidase, wherein the tumor dissociation reagent does not degrade or partially degrade membrane surface receptor.
2. The tumor dissociation reagent of claim 1 , which further does not comprise trypsin.
3. The tumor dissociation reagent of claim 1 , which further comprises DNase I.
4. The tumor dissociation reagent of claim 1 , wherein the membrane surface receptor is a checkpoint receptor.
5. The tumor dissociation reagent of claim 1 , wherein the membrane surface receptor comprises CD8, PD-1, PD-L1, TIM-3 or LAG-3 protein.
6. A method for detecting protein expression level of an immunological checkpoint marker in tumor tissue, comprising applying the tumor dissociation reagent of claim 1 to the tumor tissue.
7. The method of claim 6 , wherein the tumor dissociation reagent further comprises DNase I.
8. The method of claim 6 , wherein the tumor tissue includes tumor infiltrating immune cell.
9. The method of claim 6 , wherein the protein expression in tumor tissue is detected by flow cytometry.
10. The method of claim 6 , wherein the protein is membrane surface receptor.
11. The method of claim 10 , wherein the membrane surface receptor comprises CD8, PD-1, PD-L1, TIM-3 or LAG-3 protein.
12. A kit for tumor dissociation comprising the tumor dissociation reagent of claim 1 .
13. The kit of claim 12 , wherein the tumor dissociation reagent further comprises DNase I.
14. A method of detecting protein expression in tumor tissue by flow cytometry comprising applying the kit of claim 12 to the tumor tissue.
15. A method of preventing degradation of an immunological checkpoint marker in tumor tissue, comprising treating cells with the tumor dissociation agent of claim 1 .
16. The method of claim 15 , wherein the tumor dissociation reagent further comprises DNase I.
17. The method of claim 15 , comprising dissolving the tumor tissue with the tumor dissociation reagent, and detecting the immunological checkpoint marker by flow cytometry.
18. The method of claim 17 , wherein the tumor tissue includes tumor infiltrating immune cell.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/570,083 US11644405B2 (en) | 2016-04-15 | 2019-09-13 | Use of tumor dissociation reagent in flow cytometry |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610235031.4 | 2016-04-15 | ||
CN201610235031.4A CN105807053B (en) | 2016-04-15 | 2016-04-15 | A kind of application of the tumour dissociation reagent in FCM analysis |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/570,083 Division US11644405B2 (en) | 2016-04-15 | 2019-09-13 | Use of tumor dissociation reagent in flow cytometry |
Publications (1)
Publication Number | Publication Date |
---|---|
US20170299491A1 true US20170299491A1 (en) | 2017-10-19 |
Family
ID=56459876
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/486,562 Abandoned US20170299491A1 (en) | 2016-04-15 | 2017-04-13 | Use of tumor dissociation reagent in flow cytometry |
US16/570,083 Active 2037-08-31 US11644405B2 (en) | 2016-04-15 | 2019-09-13 | Use of tumor dissociation reagent in flow cytometry |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/570,083 Active 2037-08-31 US11644405B2 (en) | 2016-04-15 | 2019-09-13 | Use of tumor dissociation reagent in flow cytometry |
Country Status (2)
Country | Link |
---|---|
US (2) | US20170299491A1 (en) |
CN (1) | CN105807053B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116794313A (en) * | 2023-08-18 | 2023-09-22 | 江西赛基生物技术有限公司 | Kit and method for simultaneously detecting three tumor markers based on flow cytometry |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107041361A (en) * | 2017-04-20 | 2017-08-15 | 北京奥康华医学检验所有限公司 | The store method and preservation reagent of a kind of tumor tissues |
CN111575236B (en) * | 2020-03-19 | 2024-04-26 | 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) | Preparation method of active single cell suspension of human liver cancer tissue and liver tissue |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004505058A (en) | 2000-07-28 | 2004-02-19 | リポノーファ ゲゼルシャフト ミット ベシュレンクテル ハフツング | Drugs for immunotherapy of malignant tumors |
ITRM20040438A1 (en) * | 2004-09-15 | 2004-12-15 | Univ Palermo | METHOD FOR PURIFICATION AND AMPLIFICATION OF CANCER STEM CELLS. |
US20070148666A1 (en) | 2005-09-15 | 2007-06-28 | Rajeev Vibhakar | Diagnosis and Treatment of Brain Cancer |
JP5686098B2 (en) * | 2009-09-17 | 2015-03-18 | Jsr株式会社 | Dissociation method and dissociator for avidin and biotin derivative |
CA3169831A1 (en) * | 2009-10-30 | 2011-05-05 | Lola M. Reid | Multipotent stem cells from the extrahepatic biliary tree and methods of isolating same |
CN104988118A (en) * | 2015-07-08 | 2015-10-21 | 深圳爱生再生医学科技有限公司 | Method for preparing umbilical cord mesenchymal stem cells |
CN107988118A (en) | 2017-12-28 | 2018-05-04 | 四川龙蟒福生科技有限责任公司 | The fermentation medium and fermentation process of a kind of bacillus |
-
2016
- 2016-04-15 CN CN201610235031.4A patent/CN105807053B/en active Active
-
2017
- 2017-04-13 US US15/486,562 patent/US20170299491A1/en not_active Abandoned
-
2019
- 2019-09-13 US US16/570,083 patent/US11644405B2/en active Active
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116794313A (en) * | 2023-08-18 | 2023-09-22 | 江西赛基生物技术有限公司 | Kit and method for simultaneously detecting three tumor markers based on flow cytometry |
Also Published As
Publication number | Publication date |
---|---|
US11644405B2 (en) | 2023-05-09 |
US20200116622A1 (en) | 2020-04-16 |
CN105807053A (en) | 2016-07-27 |
CN105807053B (en) | 2019-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11644405B2 (en) | Use of tumor dissociation reagent in flow cytometry | |
Loktionov | Eosinophils in the gastrointestinal tract and their role in the pathogenesis of major colorectal disorders | |
Shimada et al. | Self-renewal and differentiation of reactive astrocyte-derived neural stem/progenitor cells isolated from the cortical peri-infarct area after stroke | |
Katz et al. | Translational research in vitiligo | |
Pastrana et al. | Genes associated with adult axon regeneration promoted by olfactory ensheathing cells: a new role for matrix metalloproteinase 2 | |
US20200345785A1 (en) | Phenotype profile of human retinal progenitor cells | |
CN107573412A (en) | A kind of new type natural albumen and its application | |
Chintalapudi et al. | Isolation and molecular profiling of primary mouse retinal ganglion cells: comparison of phenotypes from healthy and glaucomatous retinas | |
Anderson et al. | Human mast cell tryptase is a potential treatment for snakebite envenoming across multiple snake species | |
Acar et al. | Proteomic and biological analysis of the effects of metformin senomorphics on the mesenchymal stromal cells | |
JP2018529389A (en) | Neural progenitor cell populations and their use | |
Maksour et al. | Innovations advancing our understanding of microglia in Alzheimer's disease: from in vitro to in vivo models | |
CA3127623A1 (en) | B cell immunotherapy | |
RU2430366C1 (en) | Method of fast diagnostics of re-inoculated lymphoblastic leukemia in line akr/jy mice | |
Agathou et al. | Niche derived oligodendrocyte progenitors: a source of rejuvenation or complementation for local oligodendrogenesis? | |
McMurran | CNS Remyelination and the gut microbiota | |
Varela et al. | In vitro differentiation of myeloid suppressor cells (MDSC-like) from an immature myelomonocytic precursor THP-1 | |
Lee et al. | Thymic epithelial requirement for γδ T cell development revealed in the cell ablation transgenic system with TSCOT promoter | |
Adair | An investigation into regional dependant microglial gene expression and function in the control of hippocampal neural stem and progenitor cell regulation | |
CN117771272A (en) | CD8 + Preparation method of primitive T cells and application of primitive T cells in preparation of anti-aging drugs | |
Zucha et al. | Spatiotemporal transcriptomic map of ischemic brain injury | |
US20200131483A1 (en) | Culture System and Media for Skin Explants Providing Enhanced Viability and Enabling Molecular Studies | |
Liu et al. | Adult Neurogenesis in Peripheral Nervous System | |
WO2007028380A1 (en) | Functional in vitro immunoassay | |
Zong et al. | Discoveries in Retina Physiology and Disease Biology Using Single-Cell RNA Sequencing |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: WUXI APPTEC (SUZHOU) CO. LTD., CHINA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ZHANG, NING;ZHANG, QIYAO;LIU, YAN;AND OTHERS;SIGNING DATES FROM 20170424 TO 20170427;REEL/FRAME:042626/0190 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |